Pipeline

Clinical Trials**

Fostamatinib

Warm Antibody AIHA
Target: Spleen tyrosine kinase (SYK)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Complete
Phase 3 In Progress
Approved Not Started

Fostamatinib***

COVID-19
Target: Spleen tyrosine kinase (SYK)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Complete
Phase 3 In Progress
Approved Not Started

Fostamatinib – ACTIV4 Host Tissue****

COVID-19
Target: Spleen tyrosine kinase (SYK)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Complete
Phase 3 In Progress
Approved Not Started

Fostamatinib – NIH/NHLBI****

COVID-19
Target: Spleen tyrosine kinase (SYK)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Complete
Phase 3 Not Started
Approved Not Started

Fostamatinib – Imperial College London

COVID-19
Target: Spleen tyrosine kinase (SYK)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 In Progress
Phase 3 Not Started
Approved Not Started

R289

Oncology / Immune Diseases
Target: Interleukin receptor-associated kinases 1 and 4 (IRAK1/4)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Not Started
Phase 3 Not Started
Approved Not Started

R552 (Systemic)

Immune Diseases
Target: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical Complete
Phase 1 Complete
Phase 2 Not Started
Phase 3 Not Started
Approved Not Started

Rxxx (CNS penetrant)

CNS Diseases
Target: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)

Pre-clinical Phase 1 Phase 2 Phase 3 Approved
Pre-clinical In Progress
Phase 1 Not Started
Phase 2 Not Started
Phase 3 Not Started
Approved Not Started

KEY:

Company-sponsored Trials Select Investigator-sponsored Trials Partner-sponsored Trials

* Please see the TAVALISSE full Prescribing Information

** Investigational compounds in these indications have not been submitted for FDA review

*** This project has been funded in part by the U.S. Government under Agreement W911QY-21-9-0018

**** Sponsored by National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH)